Leading expert in breast cancer and immuno-oncology, Dr. Giuseppe Curigliano, MD, explains how a patient with metastatic triple-negative breast cancer achieved long-term survival for nearly a decade after treatment with a combination of chemotherapy and immunotherapy. He details the remarkable clinical case of a "superhero" outlier who stopped treatment after three years and remains alive with no progressive disease, attributing this success to active immune surveillance. Dr. Curigliano also discusses a proposed multi-dimensional research trial using next-generation sequencing, liquid biopsy, and microbiome analysis to identify the genomic, transcriptomic, and microbial features that explain exceptional responses to cancer therapy.
More from Integrative Medicine
More from Diagnostic Detectives Network
Metastatic Triple-Negative Breast Cancer Survival and Exceptional Responders
Jump To Section
- Clinical Case of Long-Term Survival
- Immunotherapy and Chemotherapy Combination
- The Role of Active Immune Surveillance
- Research on Outlier Patients
- Multi-Dimensional Analysis Trial
- Genomic and Transcriptomic Features
- Microbiome and Cancer Response
- Future Directions in Immunotherapy
Clinical Case of Long-Term Survival
Dr. Giuseppe Curigliano, MD, presents a compelling clinical case of a patient with metastatic triple-negative breast cancer. This patient was diagnosed nearly a decade ago with a significant disease burden, including brain metastases, lung metastases, and lymph node involvement.
Despite this aggressive presentation, the patient has achieved long-term survival, a rare outcome for this challenging breast cancer subtype. The case illustrates the potential for durable remission even in advanced-stage disease.
Immunotherapy and Chemotherapy Combination
Dr. Giuseppe Curigliano, MD, treated this exceptional responder with a combination of chemotherapy and immunotherapy. The treatment was administered within the context of a clinical trial during the early days of using immunotherapy for breast cancer patients.
The patient completed the treatment protocol and, notably, stopped all therapy after three years. She remains alive today with no evidence of progressive disease, demonstrating a complete and sustained response.
The Role of Active Immune Surveillance
Dr. Curigliano attributes this remarkable outcome to a concept known as active immune surveillance. He explains that in such outlier patients, a balance is achieved where the body's own immune system effectively controls the cancer.
"The immune system of the patient is working," states Dr. Giuseppe Curigliano, MD. This suggests that the initial combination therapy may have successfully primed the immune system to recognize and continuously suppress cancer cells, leading to long-term disease control even after treatment cessation.
Research on Outlier Patients
Dr. Anton Titov, MD, the interviewer, highlights the importance of studying these exceptional responders, or "superheroes" as Dr. Curigliano calls them. Understanding the molecular mechanisms behind their success could provide insights for improving treatments for all patients.
Dr. Giuseppe Curigliano, MD, agrees, emphasizing that these outliers represent a unique population for scientific investigation. Their cases challenge conventional survival statistics and offer a window into the potential of the human immune system to combat metastatic cancer.
Multi-Dimensional Analysis Trial
To systematically study these heroes, Dr. Curigliano is proposing a dedicated clinical trial. This research will employ a multi-dimensional analysis approach, potentially incorporating artificial intelligence to identify key predictive features.
The trial design includes comprehensive sample collection from participants. Researchers will gather blood samples for liquid biopsy, preserved tissue samples, and fecal samples for microbiome analysis to build a complete biological profile.
Genomic and Transcriptomic Features
A core component of the proposed research involves next-generation sequencing (NGS) to uncover genomic features associated with exceptional responses. This will help identify specific genetic mutations or signatures that may predict immunotherapy success.
Dr. Giuseppe Curigliano, MD, also plans transcriptomic analysis to study gene expression patterns. Comparing the genomic and transcriptomic profiles of outliers against typical patients could reveal the molecular drivers of effective immune surveillance in metastatic triple-negative breast cancer.
Microbiome and Cancer Response
Dr. Curigliano's research protocol uniquely includes the collection of fecal microbiome samples. This reflects the growing understanding that gut bacteria play a crucial role in modulating immune responses to cancer therapy.
As Dr. Anton Titov, MD, notes, the human body contains more microbial cells than human cells. Analyzing the microbiome composition of exceptional responders may reveal specific bacterial communities that enhance the efficacy of immunotherapy and contribute to long-term metastatic breast cancer survival.
Future Directions in Immunotherapy
The case presented by Dr. Giuseppe Curigliano, MD, provides hope for improving outcomes in metastatic triple-negative breast cancer. It demonstrates that durable responses are possible with current immunotherapy approaches, even in patients with extensive disease.
Future research efforts, like the multi-dimensional trial proposed by Dr. Curigliano, aim to identify biomarkers that can predict which patients will become exceptional responders. This could eventually allow clinicians to personalize treatment strategies and help more patients achieve long-term survival with metastatic cancer.
Full Transcript
Dr. Anton Titov, MD: Could you please discuss a clinical case or a composite of some clinical cases in your practice that illustrates some of the topics we have just discussed?
Dr. Giuseppe Curigliano, MD: I have a patient with metastatic triple-negative breast cancer that was diagnosed with brain metastases, lung metastases, and lymph nodal disease almost ten years ago. What I did for this patient is give a combination of chemotherapy and immunotherapy. In the beginning, when we started using immunotherapy in breast cancer patients, I must confess that she completed the treatment in the context of a clinical trial.
After three years, she stopped treatment, and she is still alive with no progressive disease. This is an example of a patient with an excellent immune response following chemotherapy and immune checkpoint inhibitors. I believe that in this patient, you have a balance within immune surveillance that is very active, with the disease under control because the immune system is working.
Dr. Anton Titov, MD: So such patients with oligometastatic disease are statistically outliers. I am sure that a lot of people, including yourself, were curious as to what is the molecular nature of active immune surveillance, as you mentioned. What kind of research-based studies do you think could be done on such patients? I am sure such excellent responders exist around the world.
Dr. Giuseppe Curigliano, MD: What we are doing actually is proposing a trial including NGS and liquid biopsy exactly in this patient population of outliers. We are collecting blood samples, tissue samples, and fecal microbiome samples in the stool. I am quite sure that in a multi-dimensional analysis, we will also be using artificial intelligence.
We may probably identify which are the features from the genomic point of view, from the transcriptomic point of view, from the microbiome point of view that explains why some patients are outliers. Or as I call them, heroes. Those patients are superheroes; they survived metastatic cancer.
Dr. Anton Titov, MD: The microbiome is a very interesting point. There was a lot of research going on. There are more microbes in the body than there are human cells. I think we should remember that.